EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)

Dorota Stefanicka-Wojtas, Donata Kurpas

Journal of Personalized Medicine · 21.02.2023 · 13 (3) · 380

DOI: 10.3390/jpm13030380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 21.02.2023. Verfasst von Dorota Stefanicka-Wojtas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial's Department, Wroclaw Medical University, 50-556 Wroclaw, Poland. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, European Union’s Horizon 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution.

Methods

Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine.

Results

This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation.

Conclusions

Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation.

Schlagwörter

Stichwörter der Autor:innen

barriersfacilitatorshealthcare systemsinterregional cooperationpersonalized medicine

Autor:innen und Institutionen

  • Clinical Trial's Department, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Family Medicine Department, Wroclaw Medical University, 51-141 Wroclaw, Poland.

Förderung

  • European Commission
  • European Union’s Horizon 2020

Zitieren

APA

Stefanicka-Wojtas, D., & Kurpas, D. (2023). Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). Journal of Personalized Medicine, 13(3), 380. https://doi.org/10.3390/jpm13030380

Vancouver

Stefanicka-Wojtas D, Kurpas D. Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). Journal of Personalized Medicine. 2023;13(3):380. doi:10.3390/jpm13030380

BibTeX
@article{StefanickaWojtas2023,
  author = {Stefanicka-Wojtas, Dorota and Kurpas, Donata},
  title = {Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {380},
  doi = {10.3390/jpm13030380}
}
Kostenlos starten →